Tags : RMS

Celgene to Present Results of Two P-III Trial SUNBEAM and

Shots: The two P-III trials SUNBEAM (N=1346) and RADIANCE (N=1320) involves assessing of two doses of ozanimod PO (0.92 & 0.46 mg, equivalent to 1 & 0.5 mg ozanimod HCI) vs 1L Avonex in RMS patients for @12 mos. & @24 mos. respectively P-III SUNBEAM & RADIANCE Part B results: early & advance RMS (1 […]Read More